Your browser doesn't support javascript.
loading
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Mitchell, Jennifer M; Bogenschutz, Michael; Lilienstein, Alia; Harrison, Charlotte; Kleiman, Sarah; Parker-Guilbert, Kelly; Ot'alora G, Marcela; Garas, Wael; Paleos, Casey; Gorman, Ingmar; Nicholas, Christopher; Mithoefer, Michael; Carlin, Shannon; Poulter, Bruce; Mithoefer, Ann; Quevedo, Sylvestre; Wells, Gregory; Klaire, Sukhpreet S; van der Kolk, Bessel; Tzarfaty, Keren; Amiaz, Revital; Worthy, Ray; Shannon, Scott; Woolley, Joshua D; Marta, Cole; Gelfand, Yevgeniy; Hapke, Emma; Amar, Simon; Wallach, Yair; Brown, Randall; Hamilton, Scott; Wang, Julie B; Coker, Allison; Matthews, Rebecca; de Boer, Alberdina; Yazar-Klosinski, Berra; Emerson, Amy; Doblin, Rick.
Afiliação
  • Mitchell JM; Department of Neurology, University of California San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.
  • Bogenschutz M; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA. jennifer.mitchell@ucsf.edu.
  • Lilienstein A; Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA.
  • Harrison C; Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA.
  • Kleiman S; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.
  • Parker-Guilbert K; Kleiman Consulting and Psychological Services, Sayreville, NJ, USA.
  • Ot'alora G M; KPG Psychological Services LLC, Brunswick, ME, USA.
  • Garas W; Aguazul-Bluewater Inc., Boulder, CO, USA.
  • Paleos C; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • Gorman I; Aguazul-Bluewater Inc., Boulder, CO, USA.
  • Nicholas C; Nautilus Sanctuary, New York, NY, USA.
  • Mithoefer M; Fluence, Woodstock, NY, USA.
  • Carlin S; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Poulter B; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.
  • Mithoefer A; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • Quevedo S; Medical University of South Carolina, Charleston, SC, USA.
  • Wells G; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA.
  • Klaire SS; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • van der Kolk B; Aguazul-Bluewater Inc., Boulder, CO, USA.
  • Tzarfaty K; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • Amiaz R; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • Worthy R; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Shannon S; San Francisco Insight and Integration Center, San Francisco, CA, USA.
  • Woolley JD; San Francisco Insight and Integration Center, San Francisco, CA, USA.
  • Marta C; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
  • Gelfand Y; Boston University School of Medicine, Boston, MA, USA.
  • Hapke E; MDMA Therapy Training Program, MAPS Public Benefit Corporation, San Jose, CA, USA.
  • Amar S; Chaim Sheba Medical Center, Tel HaShomer, Israel.
  • Wallach Y; Ray Worthy Psychiatry LLC, New Orleans, LA, USA.
  • Brown R; Wholeness Center, Fort Collins, CO, USA.
  • Hamilton S; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Wang JB; New School Research LLC, North Hollywood, CA, USA.
  • Coker A; Zen Therapeutic Solutions, Mt Pleasant, SC, USA.
  • Matthews R; University of Toronto, Toronto, Ontario, Canada.
  • de Boer A; Dr Simon Amar Inc., Montreal, Quebec, Canada.
  • Yazar-Klosinski B; Be'er Ya'akov Ness Ziona Mental Health Center, Be'er Ya'akov, Israel.
  • Emerson A; Fluence, Woodstock, NY, USA.
  • Doblin R; Stanford School of Medicine, Stanford, CA, USA.
Nat Med ; 27(6): 1025-1033, 2021 06.
Article em En | MEDLINE | ID: mdl-33972795
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Estresse Pós-Traumáticos / N-Metil-3,4-Metilenodioxianfetamina / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Estresse Pós-Traumáticos / N-Metil-3,4-Metilenodioxianfetamina / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos